Phaseline

Companies › PolTREG

PolTREG: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine; next expected readout Dec 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)
Ex vivo expanded regulatory T cell therapy
CD4, CD25, IL2RAPhase 2Presymptomatic Diabetes Type 1 (Stage 1)Dec 2032
rituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Presymptomatic Diabetes Type 1 (Stage 1)Dec 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06688331ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)Phase 2Presymptomatic Diabetes Type 1 (Stage 1)Metabolic and endocrineDec 2032
NCT06688331rituximabPhase 2Presymptomatic Diabetes Type 1 (Stage 1)Metabolic and endocrineDec 2032

Targets

CD4 (1) CD25 (1) IL2RA (1) MS4A1 (1)

Companies with the same targets

Roche Regeneron Pharmaceuticals Biocad Acerta Pharma GSK TaiMed Biologics Nektar Therapeutics Mural Oncology GI Innovation Synthekine

Companies built like this

Actimed Therapeutics Verdiva Bio Dev Protalix Veru Skye Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.